- AVTX Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
424B3 Filing
Avalo Therapeutics (AVTX) 424B3Prospectus supplement
Filed: 9 Aug 18, 7:55am
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant. |
Date: August 9, 2018 | By: | /s/ Peter Greenleaf |
Name: | Peter Greenleaf | |
Title: | Chief Executive Officer (Registrant’s Principal Executive Officer) | |
Date: August 9, 2018 | By: | /s/ Joseph M. Miller |
Name: | Joseph M. Miller | |
Title: | Chief Financial Officer (Registrant’s Principal Financial and Accounting Officer) |